Amylyx Pharmaceuticals, Inc.
AMLX
Rangering i aksjer
#4499
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aksjekurs
$27.25
Sist synkronisert: 2026-10-19
Markedsverdi
$3.42B
Endring (1 dag)
3.45%
Endring (1 år)
77.29%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Utbytteavkastning for Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (aksjesymbol: AMLX) sin utbytteavkastning (TTM) per 2023-12-31 er: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Amylyx Pharmaceuticals, Inc. (AMLX) fra 2019 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
